Good MorningThe S&P 500 pulled back on Wednesday due to an increasingly tepid outlook put forth by the retail sector. The latest report to weigh on the market comes from Target which missed estimates on the top and bottom lines, the bottom line by a very wide margin. The report highlights a growing problem in the retail sector in the form of bloating inventories that spells bad news for earnings and good news for consumers. With inventories at unusually high levels, retailers may be forced to follow in Target's footsteps and enter a new age of deep discounting to move merchandise.
The decline in stocks was curbed, however, by the FOMC minutes. The minutes indicate the Fed is ready to hike rates until inflation comes down substantially from its current high levels but gave no indication of the pace or timing of hikes. The market is pricing in a 50 basis point hike at the next meeting but there are still several inflation reports due out before then. Featured: “By July 30, Elon Musk’s Prophecy Will Fulfill Itself” (Ad) 
|
Technology | | ON Semiconductor (NASDAQ: ON) has taken a leadership role within its industry lately, as the stock notched gains of 26.11% in the past month and 28.21% in the past three months.
Other large-cap chip companies, such as Nvidia (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD) have shown fundam... Read the Full Story |
|
From Our Partners | | The SpaceX IPO wasn't the big trade - according to Larry Benedict, founder of The Opportunistic Trader, it was the trigger. Benedict, who delivered a 279% return on cash in 2025 across a 20-year winning streak, says the listing launched what he calls the 'Final Phase of Elon's Master Plan.'
He's identified one specific ticker - not SpaceX, Tesla, or any Elon-affiliated company - that he believes could see billions in inflows as this phase unfolds. He calls it his trade of the year. | | Watch the video now to get the ticker name and full trade details |
|
Basic Materials | | Metal miner Rio Tinto (NYSE: RIO) is up 7.8% since reporting first-half earnings in late July. Earnings declined 29%, to $2.73 per share, while revenue dropped 10% to $14.9 billion.
Although that was actually an earnings beat, the company also slashed its dividend in response to lower iron ore pri... Read the Full Story |
|
Aerospace | |
If you've ever had an interest in business aviation, combat vehicles, weapons systems and munitions or shipbuilding and ship repair, General Dynamics Corporation (NYSE: GD) might be right up your alley.
General Dynamics pays an annual dividend of $5.04 per share and has a dividend yield of 2.1%.... Read the Full Story |
|
From Our Partners | | Gold just broke another record - a classic flight-to-safety signal that the smartest money on Wall Street is already acting on. With the NASDAQ pricing in optimism over fundamentals and global tensions continuing to rise, a market correction could arrive without warning.
Our research team just released a free crash-protection guide identifying which stocks and sectors can hold strong even when the broader market crumbles. | | Download your free crash protection guide today |
|
Medical | |
Agilent Technologies (NYSE: A) is a highly-valued stock for the low 0.6% dividend that it pays but the Q2 results once again prove the company’s worth. The results include a top and bottom line beat as well as improved guidance that has the shares moving higher in their wake. With competitor... Read the Full Story |
|
Retail/Wholesale | |
Lowe’s (NYSE: LOW) Q2 results may look weaker than Home Depot’s (NYSE: HD) at first glance but there is a meaningful difference in the guidance. Where Home Depot’s outlook was improved it is only in line with the consensus and projects a weakening in the 2nd half, Lowe’s wa... Read the Full Story |
|
From Our Partners | | Trader Jeffry Turnmire has found a way to track institutional dark pool activity and act on it using a class of securities he calls Supercharged Tickers.
These instruments are designed to deliver double or triple-digit returns similar to options - but without the strikes, expiration dates, or time decay that trip up even experienced traders. | | See how Supercharged Tickers work and get started today |
|
Retail/Wholesale | |
Target’s (NYSE: TGT) Q2 results reinforce a problem facing the retail sector that was only hinted at by Walmart (NYSE: WMT) and Home Depot (NYSE: HD) earlier in the week. The company’s efforts to combat supply chain and inventory hurdles are catching up with it at the same time that de... Read the Full Story |
|
Markets | | Activision Blizzard (NASDAQ: ATVI) stock hasn’t gotten much traction since its earnings report on August 1.
On the one hand, that lack of movement is not particularly surprising, given that Microsoft has offered to buy the game software and console maker for $68.7 billion, or $95 per share. ... Read the Full Story |
|
Consumer Staples | |
Coca-Cola (NYSE:KO) and PepsiCo (NASDAQ:PEP) are part of the consumer staples sector. This sector includes many of the leading defensive stocks. A feature of the best companies in this sector is that they offer products that consumers will buy no matter what is happening in the broader economy.
... Read the Full Story |
|
Auto/Tires/Trucks | |
Mr. President, investors were banking on you signing that enormous climate, health, and tax bill.
With the President signing off on the landmark $430 billion package that earmarks a sizable chunk to clean energy policies, electric vehicle (EV) stocks have been, well, electric as of late.
Since t... Read the Full Story |
|
Technology | |
Shares of Apple (NASDAQ: AAPL) are approaching their 52-week high and many analysts believe AAPL stock could cross over $200 per share by the end of the year. If it does so, it won’t be exclusively due to iPhone sales (although those sales still are strong).
As many shareholders know, App... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. | | View Today's Stock Pick |
|
